Employees: 337
Size Qyuns Therapeutics (2509.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $428M, the 782nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$14.59 on 18 Nov 2026.
Performance Over six months the shares fell 10.8%, against -22.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 230.3% over the last twelve months (peer median +1.7%); the operating margin is 56.4% (peer median -17.2%).
Valuation It trades at 10.2× forward earnings against a peer median of 33.9× (2nd cheapest of 6).
Capital Return on invested capital runs 87.9 points above its cost of capital (6.9% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.14B | HK$875M | HK$172M | HK$0 | HK$0 |
| Revenue growth | — | +408% | — | — | — |
| Gross profit | HK$989M | HK$740M | HK$64.5M | -HK$35.7M | -HK$35.5M |
| EBITDA | HK$679M | HK$391M | -HK$354M | -HK$549M | -HK$353M |
| Net income | HK$607M | HK$341M | -HK$364M | -HK$561M | -HK$347M |
| Free cash flow | HK$549M | HK$414M | -HK$214M | -HK$352M | -HK$299M |
| Capital expenditure | HK$16.2M | HK$8.27M | HK$1.91M | HK$8.78M | HK$26.5M |
| Total debt | n/a | HK$646M | HK$561M | HK$381M | HK$331M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2509.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.8% | -13.4% | 7th highest of 21 |
| 6-month return | -10.8% | -22.5% | 9th highest of 21 |
| Distance from 52-week high | -40.5% | -46.2% | 10th highest of 21 |
| Revenue growth (TTM) | +230.3% | +1.7% | 4th highest of 17 |
| Operating margin | 56.4% | -17.2% | 2nd highest of 17 |
| Forward P/E | 10.2× | 33.9× | 2nd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -19.5% | 3.0% | least demanding of 7 |
| ROIC minus cost of capital | +87.9 pp | -12.7 pp | highest of 16 |
| EV / EBITDA | 4.4× | n/a | — |
| Net debt / EBITDA | -0.6× | -5.5× | most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 10.2× | -19.5% | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 26.2× | 5.3% | +70.5% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 170.0× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | n/a | 4.0% | -62.3% |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 39.4× | 2.1% | +0.5% |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 33.9× | 7.7% | +7.3% |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | n/a | -15.3% | +197.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | n/a | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 5.7× | -18.8% | -36.1% |